|
Market Closed -
Nasdaq
16:30:00 2026-09-25 EDT
|
5-day change | 1st Jan Change | ||
| 3.580 USD | -0.28% |
|
+0.56% | -34.53% |
| 08-11 | Bolt Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
| 05-12 | Bolt Biotherapeutics reports first quarter 2026 financial results | RE |
Company Valuation: Bolt Biotherapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 182.7 | 48.96 | 42.52 | 20.48 | 10.5 | 6.896 | - | - |
| Change | - | -73.2% | -13.15% | -51.84% | -48.75% | -34.29% | - | - |
| Enterprise Value (EV) | -3.524 | -97.32 | -39.45 | 20.48 | 10.5 | 6.896 | 6.896 | 6.896 |
| Change | - | -2,661.37% | 59.46% | 151.92% | -48.75% | -34.29% | 0% | 0% |
| P/E | -1.65x | -0.55x | -0.61x | -0.32x | -0.31x | -0.15x | -0.18x | -0.12x |
| PBR | 0.73x | 0.29x | 0.38x | - | - | - | - | - |
| PEG | - | 0x | 0x | 0.03x | 0x | -0x | 0x | -0x |
| Capitalization / Revenue | 145x | 8.55x | 5.4x | 2.66x | 1.36x | 34.5x | 1.97x | 0.86x |
| EV / Revenue | -0x | -0x | -0x | 0x | 0x | 34.5x | 1.97x | 0.86x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | 0x | 0x | 0x | -0x | -0x | -0.11x | -0.15x | -0.11x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -59.4 | -47.2 | -36.6 | -33 | -17.85 | -23.36 | -20.19 | -30.84 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 1.26 | 5.729 | 7.876 | 7.69 | 7.695 | 0.2 | 3.5 | 8 |
| EBITDA | -83.1 | -79.08 | -65.12 | - | - | - | - | - |
| EBIT 1 | -92.79 | -90.32 | -76.2 | -73.05 | -36.11 | -65 | -47.5 | -60 |
| Net income 1 | -98.59 | -88.1 | -69.2 | -63.12 | -33.38 | -47.4 | -47.5 | -60 |
| Net Debt | -186.2 | -146.3 | -81.97 | - | - | - | - | - |
| Reference price 2 | 98.000 | 26.000 | 22.400 | 10.702 | 5.468 | 3.580 | 3.580 | 3.580 |
| Nbr of stocks (in thousands) | 1,864 | 1,883 | 1,898 | 1,914 | 1,919 | 1,926 | - | - |
| Announcement Date | 3/30/22 | 3/29/23 | 3/21/24 | 3/24/25 | 3/12/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.15x | - | - | - | 6.9M | |
| 21.09x | 7.5x | 15.07x | 1.41% | 72.26B | |
| 31.3x | 9.02x | 28.11x | 0.04% | 60.24B | |
| 32.1x | 6.85x | 17.78x | -.--% | 27.73B | |
| -72.3x | 13.87x | -75.56x | -.--% | 25.73B | |
| -15.17x | 5.73x | -7.2x | -.--% | 24.75B | |
| 28.46x | 5.35x | 17.81x | -.--% | 20.74B | |
| 42.74x | 15.97x | 32.4x | 0.35% | 15.06B | |
| 17.96x | 5.35x | 12.5x | -.--% | 14.41B | |
| 1015.79x | 35.53x | 613.78x | -.--% | 14.23B | |
| Average | 110.18x | 11.69x | 72.74x | 0.2% | 27.52B | |
| Weighted average by Cap. | 65.46x | 9.84x | 39.70x | 0.4% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- BOLT Stock
- Valuation Bolt Biotherapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
